SRF231 is an investigational monoclonal antibody that inhibits the activity of CD47, a cell surface protein which plays an important role in allowing tumor cells to escape destruction by a particular type of immune cell called a macrophage.
Surface has initiated a Phase 1 clinical trial which is currently evaluating the safety and tolerability of SRF231 in multiple ascending doses with the goal of establishing a recommended dose for further study as monotherapy in patients with specific solid and hematologic malignancies. Subsequently, and depending upon the results of our earlier trial data, we intend to evaluate the safety and efficacy of SRF231 in combination with other cancer therapies in patients.
SRF373 / NZV930
SRF373, also known as NZV930, is an investigational monoclonal antibody that inhibits the activity of CD73, an ectoenzyme that plays a key role in the generation of extracellular adenosine which potently suppresses the immune response.
A first-in-human study of SRF373 / NZV930 is being led by Novartis which was granted a worldwide exclusive license to develop and commercialize NZV930 as part of its broad strategic collaboration with Surface. The Phase I study will evaluate the safety, tolerability, and preliminary anti-tumor activity of NZV930 as a single agent and in combination with other cancer immunotherapies. The initial dose escalation portion of the trial will include patients with triple negative breast cancer, ovarian cancer, microsatellite stable colon cancer, pancreatic cancer, non-small cell lung cancer, and renal cell carcinoma.